Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Royalty Pharma acquired royalty rights on global sales of rimegepant (BHV-3000) and BHV-3500 for $100M, with tiered royalties starting at 2.10% on annual net…
Biohaven and Royalty Pharma expanded the partnership with a $450M package — up to $250M for zavegepant funding (3% royalty plus 0.4% on Nurtec ODT) and…
BioPharma Dive validated the Royalty Pharma thesis ex-post: Pfizer paid $150M upfront plus $350M equity at a 25% premium for ex-US Nurtec rights after the drug…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Royalty Pharma agreed to purchase up to $200M in Series A Preferred Shares of Biohaven to fund Biohaven's $105M acquisition of an FDA Priority Review Voucher and general corporate uses for the rimegepant NDA. Royalty Pharma provided $125M at closing with up to an additional $75M available upon FDA acceptance of the rimegepant NDA.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Royalty Pharma / Biohaven Pharmaceutical Holding Co. Ltd. (rimegepant funding) (this deal) | 2019 | $200M | — |
| Royalty Pharma / Neurimmune AG (NI006 license) | 2026 | $425M | — |
| Royalty Pharma / BeOne Medicines Ltd. | 2025 | $950M | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
← Browse all deals · How we score deals
More: 2019 deals · Royalty Pharma deals · Neurology deals